1. Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence.
- Author
-
Nadal E, Rifi N, Kane S, Mbacke S, Starkman L, Suero B, Le H, and Samjoo IA
- Subjects
- Humans, Oncogene Proteins, Fusion genetics, Treatment Outcome, Antineoplastic Agents therapeutic use, Antineoplastic Agents adverse effects, Gene Fusion, Crizotinib therapeutic use, Crizotinib adverse effects, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung mortality, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Lung Neoplasms mortality, Proto-Oncogene Mas, Proto-Oncogene Proteins genetics, Protein-Tyrosine Kinases genetics, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects
- Abstract
Background: Crizotinib was approved to treat patients with advanced non-small cell lung cancer (aNSCLC) with ROS proto-oncogene 1 (ROS1) gene fusion in 2016. We conducted a systematic literature review to identify real-world evidence (RWE) studies and estimated the efficacy and safety of crizotinib using meta-analyses (MA) for objective response rate (ORR), real-world progression-free survival (PFS), and overall survival (OS)., Methods: We searched MEDLINE®, Embase, and Cochrane CENTRAL from January 2016 to March 2023 using Ovid® for published single-arm or comparative RWE studies evaluating patients (N ≥ 20) receiving crizotinib monotherapy for aNSCLC with ROS1 gene fusion. Pooled estimates for ORR and grade 3/4 adverse events (AEs) were derived using the metafor package in R while pooled estimates for median real-world PFS (rwPFS) and OS were derived using reconstructed individual patient data from published Kaplan-Meier curves. The primary analysis included all studies regardless of crizotinib line of therapy; a subgroup analysis (SA) was conducted using studies evaluating patients receiving first-line crizotinib., Results: Fourteen studies met the eligibility criteria and were considered feasible for MA. For the primary analysis, the pooled ORR (N = 9 studies) was 70.6 % (95 % confidence interval [CI]: 57.0, 81.3), median rwPFS was 14.5 months (N = 11 studies), and OS was 40.2 months (N = 9 studies). In the SA, the pooled ORR (N = 4 studies) was 81.1 % (95 % CI: 76.1, 85.2) and the median rwPFS (N = 4 studies) and OS (N = 2 studies) were 18.1 and 60 months, respectively. All MAs were associated with significant heterogeneity (I
2 > 25 %). Grade 3/4 AEs occurred in 18.7 % of patients (pooled estimate)., Conclusion: The results from this study are consistent with clinical trial data and, taken collectively, supports crizotinib as a safe and effective treatment across different lines of therapy in patients with ROS1 aNSCLC in the real-world setting., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Ernest Nadal is a consultant for and receives research funding from Pfizer. Nada Rifi and Hannah Le are employees of Pfizer and own Pfizer stock. Imtiaz A. Samjoo, Sarah Kane, Sokhna Mbacke, Lindsey Starkman, and Beatrice Suero are employees of EVERSANA, Canada, a paid consultant to Pfizer in connection with the development of this manuscript. EN is a consultant for and receives research funding from Pfizer. NR and HL are employees of Pfizer and own Pfizer stock. IAS, SK, SM, LS, and BS are employees of EVERSANA, Canada, a paid consultant to Pfizer in connection with the development of this manuscript., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF